Search details
1.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Br J Haematol
; 204(3): 849-860, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37996986
2.
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Haematologica
; 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38841789
3.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Hematol Oncol
; 42(3): e3272, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38595316
4.
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Ann Hematol
; 103(6): 2021-2031, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38280061
5.
Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Eur J Haematol
; 112(5): 662-677, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38168033
6.
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Jpn J Clin Oncol
; 54(4): 376-385, 2024 Apr 06.
Article
in English
| MEDLINE | ID: mdl-38183209
7.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38526621
8.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38538963
9.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 17.
Article
in English
| MEDLINE | ID: mdl-38755516
10.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(6): 681-688, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38649648
11.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 29(6): 700-705, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38696053
12.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38353907
13.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38494578
14.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38517658
15.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 29(6): 689-699, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38578596
16.
[Current status and future perspective of clinical trials for patients with multiple myeloma].
Rinsho Ketsueki
; 65(5): 420-427, 2024.
Article
in Japanese
| MEDLINE | ID: mdl-38825522
17.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Cancer Sci
; 114(8): 3461-3465, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37232264
18.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36433829
19.
An update on the developments in the treatment of adult T-cell leukemia-lymphoma: current knowledge and future perspective.
Jpn J Clin Oncol
; 53(12): 1104-1111, 2023 Dec 07.
Article
in English
| MEDLINE | ID: mdl-37592900
20.
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Hematol Oncol
; 40(4): 667-677, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35142384